The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
Development services for gene and cell therapies is planned to begin first in 2025
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
Subscribe To Our Newsletter & Stay Updated
